Pfizer’s Biohaven Bet Pays Off Again as Migraine Nasal Spray Wins Approval 3/10/2023

Clinical Hold on Fulcrum's Sickle Cell Hopeful Triggered by Hematologic Malignancies Profile 3/10/2023

Independent Panel Recommends Polivy in First Line LBCL Despite FDA Reservations 3/10/2023

Clene's Nanocrystal ALS Treatment Bounces Back with Positive Data 3/9/2023

Bayer Plans to Double Down on US Pharma R&D in 2023 3/9/2023

AstraZeneca Notches Back-to-Back Late-Stage Wins in Lung Cancer 3/9/2023

How ChatGPT Can–and Can't–Help Your Job Search 3/9/2023

QurAlis’ Biomarker-Driven Approach Attracts $88M in Series B 3/9/2023

Lilly’s Alzheimer’s Struggles Continue as Preclinical Disease Asset Fails Phase III 3/9/2023

Closing the Opportunity Gap: How Inceptor Bio Supports Women Leaders 3/9/2023

In Tough Market, CODA Quietly Shuts Doors 3/8/2023

BioMarin Answers BridgeBio's Challenge with sNDA for Achondroplasia 3/8/2023

FDA Accepts Mesoblast’s Ryoncil Resubmission for Pediatric GVHD 3/8/2023

Co-working could Drive Innovation, Distribution of Talent Across U.S. 3/8/2023

The Decade of RNA Delivery – Beyond the Liver 3/8/2023

Rapport Therapeutics Snags $100M for Precision Approach to Neurological Diseases 3/7/2023

Moderna Eyes Accelerated Approval for mRNA Cancer Vaccine 3/7/2023

Lilly-Backed Volastra Enters Clinic with Amgen’s KIF18A Inhibitor 3/7/2023

Merck Preps Potential First Oral PCSK9 Inhibitor for Phase III 3/7/2023

Small Study of BridgeBio's Dwarfism Drug Indicates Advantage over BioMarin 3/7/2023